A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va
A phase 3 trial of Cabozantinib in thyroid cancer, run by Exelixis, active and no longer recruiting.
Overview
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy is a phase 3 interventional study registered as NCT03690388 by Exelixis, with 187 participants enrolled, started 2018-10-05 and due to reach its primary completion in 2020-08-19. Interventions recorded: Cabozantinib, Placebo. Conditions listed: Differentiated Thyroid Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece
Shares Exelixis, Cabozantinib.
- TargetAXL
Shares Cabozantinib, Thyroid cancer.
- TrialStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Shares Exelixis, Cabozantinib.
- TrialPan Tumor Rollover Study
Shares Exelixis, Cabozantinib.
- CancerAdrenocortical carcinoma
Shares Exelixis, Cabozantinib.
- PathwayThyroid cancer (KEGG map)
Shares Cabozantinib, Thyroid cancer.
- CancerMultiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Shares Cabozantinib, Thyroid cancer.